Breaking News

Ajinomoto Althea Launches Corynex Platform

By Kristin Brooks | January 9, 2014

Platform provides successful scale up of protein for Phase I trial

Ajinomoto Althea, Inc. has launched a protein production platform, Corynex, to produce secreted, soluble, properly folded proteins from microbial fermentation. The company has recently finalized the production process for a therapeutic protein scheduled to enter a Phase I trial using the platform to scale up production from test tubes to small scale fermentation. The Corynex platform, based on the bacterium Corynebacterium glutamicum, secretes proteins into the cell culture supernatant in active form with minimal host contaminants, according to the company.
 
A yield of approximately 1 gram per liter was achieved, despite the difficult nature of the protein, and column chromatography purification achieved a purity of greater than 98%, according to the company.
 
"We are extremely pleased to have successfully and fully demonstrated the Corynex platform process here in San Diego. With the addition of Corynex, we are now offering an even more complete suite of solutions to our customers from process development through clinical manufacturing for a very wide variety of recombinant proteins," said Kristin DeFife, director of biologics manufacturing at Ajinomoto Althea.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks